海外の治験の状況「COVID-19」での検索結果
90件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Not recruiting
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR
- Acute Myelogenous Leukemia
- United States
- 2017-02-28
Not recruiting
- Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
- EGFR Activating Mutation;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.L858R;Non-Squamous Non-Small Cell Lung Carcinoma;Stage IV Non-Small Cell Lung Cancer AJCC v7
- United States
- 2012-02-07
Not recruiting
- CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
- Acute Myelogenous Leukemia;Acute Myelogenous Leukemia;Acute Myelogenous Leukemia;Acute Myelogenous Leukemia
- United States
- 2012-07-10
Not recruiting
- Biological Investigations in Active Surveillance (BIAS) IGAR 2008 I 19 in Prostate Cancer Using High Field MRI (3 Tesla), PET, and Biomarkers
- Prostate Cancer;Prostate Cancer
- Canada
- 2008-05-12
Not recruiting
- Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
- Primary Immunodeficiency;Common Variable Hypogammaglobulinemia;X-linked Hypogammaglobulinemia;Hypogammaglobulinemia;Immunodeficiency With Hyper-IgM;Wiskott-Aldrich Syndrome;Primary Immunodeficiency;Common Variable Hypogammaglobulinemia;X-linked Hypogammaglobulinemia;Hypogammaglobulinemia;Immunodeficiency With Hyper-IgM;Wiskott-Aldrich Syndrome;Primary Immunodeficiency;Common Variable Hypogammaglobulinemia;X-linked Hypogammaglobulinemia;Hypogammaglobulinemia;Immunodeficiency With Hyper-IgM;Wiskott-Aldrich Syndrome;Primary Immunodeficiency;Common Variable Hypogammaglobulinemia;X-linked Hypogammaglobulinemia;Hypogammaglobulinemia;Immunodeficiency With Hyper-IgM;Wiskott-Aldrich Syndrome
- United States
- 2006-01-18
Recruiting
- Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
- Severe Combined Immunodeficiency (SCID);Immunodeficiency With Predominant T-cell Defect, Unspecified;Severe Chronic Neutropenia;Chronic Granulomatous Disease (CGD);Hyper IgE Syndromes;Hyper IgM Deficiencies;Wiskott-Aldrich Syndrome;Mendelian Susceptibility to Mycobacterial Disease;Common Variable Immune Deficiency (CVID)
- United States
- 2013-04-26
Not recruiting
- Rifaximin in Patients With Monoclonal Gammopathy
- IgA Monoclonal Gammopathy;IgG Monoclonal Gammopathy;IgM Monoclonal Gammopathy;Light Chain Deposition Disease;Monoclonal Gammopathy;Smoldering Waldenstrom Macroglobulinemia;Waldenstrom Macroglobulinemia;Gammopathy, Monoclonal;Gammopathy Igg
- United States
- 2019-01-28
Recruiting
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
- ALK Gene Rearrangement;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.L858R;Stage IB Non-Small Cell Lung Carcinoma AJCC v7;Stage II Non-Small Cell Lung Cancer AJCC v7;Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- United States
- 2014-07-15
Recruiting
- Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma;EGFR Activating Mutation;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.G719X;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.L861Q;EGFR NP_005219.2:p.T790M;Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;Stage III Non-Small Cell Lung Cancer AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7;Stage IIIB Lung Non-Small Cell Cancer AJCC v7;Stage IV Non-Small Cell Lung Cancer AJCC v7
- United States
- 2015-08-10
Recruiting
- Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
- EGFR Activating Mutation;EGFR Exon 19 Deletion Mutation;EGFR NP_005219.2:p.G719X;EGFR NP_005219.2:p.L858R;EGFR NP_005219.2:p.L861Q;EGFR T790M Mutation Negative;Recurrent Lung Non-Small Cell Carcinoma;Stage III Non-Small Cell Lung Cancer AJCC v7;Stage IIIA Non-Small Cell Lung Cancer AJCC v7;Stage IIIB Lung Non-Small Cell Cancer AJCC v7;Stage IV Non-Small Cell Lung Cancer AJCC v7
- Canada, United States
- 2015-07-20
